Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2016065264 |
Title |
Diterpenoid Derivatives and Methods of Use Thereof. |
Abstract |
Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/ NF-kappa pathways. The diseases associated include, but are not limited to a fibrotic disease such as lung fibrosis, liver fibrosis, kidney fibrosis, and scleroderma, or a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease, and sickle cell disease. |
Applicant(s) |
Biogen Ma Inc |
Representative Drug(s) |
D09FZF |
Drug Info
|
EC50 < 500 nM |
Click to Show More |
[1] |
2
|
D0Q9QQ
|
Drug Info
|
EC50 < 500 nM
|
[1] |
Patent ID |
WO2012125488 |
Title |
C4-Monomethyl Triterpenoid Derivatives and Methods of Use Thereof. |
Abstract |
Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided. |
Applicant(s) |
Reata Pharmaceuticals, Inc |
Representative Drug(s) |
D0N9GH |
Drug Info
|
IC50(RAW264.7 cells) = 0.7 nM |
Click to Show More |
[1] |
2
|
D01GTU
|
Drug Info
|
IC50(RAW264.7 cells) = 1 nM
|
[1] |
Patent ID |
WO2016059269 |
Title |
Compounds Derived From 3-Alkylamino-1H-Indole Acrylate, and The Use Thereof In The Treatment of Neurodegenerative Diseases. |
Abstract |
The invention relates to the methods for producing derivatives of 3-alkylamino-1H-indole acrylate (I) with transcription factor Nrf2-inducing activity, free radical scavenging activity and neuroprotective ability. The invention also relates to the use of the derivatives according to the invention for the treatment of diseases, the pathogenesis of which involves oxidative stress, or diseases involving the deregulation of the activity of phase II genes activated by the factor Nrf2, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, ictus or amyotrophic lateral sclerosis. |
Applicant(s) |
Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Princesa Universidad Autonoma De Madrid Dns Neuroscience |
Representative Drug(s) |
D01PKZ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0FH6P
|
Drug Info
|
N.A.
|
[1] |
3
|
D0FM3Q
|
Drug Info
|
N.A.
|
[1] |
4
|
D0L1JQ
|
Drug Info
|
N.A.
|
[1] |
5
|
D0MX0Q
|
Drug Info
|
N.A.
|
[1] |
6
|
D0SA1N
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2015187934 |
Title |
Functionalized Hetroaryl Enones Exhibiting Nrf2 Activation and Their Method of Use. |
Abstract |
Pharmaceutical compositions are disclosed, which include functionalized hetroaryl enones and are useful for treating or preventing a disease, disorder or condition associated with an NRF2-regulated pathway and/or which involves oxidative stress. |
Applicant(s) |
Cureveda, Llc |
Representative Drug(s) |
D02SPI |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0EO3S
|
Drug Info
|
N.A.
|
[1] |
3
|
D0G1LS
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2013163344 |
Title |
2.2-Difluoropropionamide Derivatives of Bardoxolone Methyl, Polymorphic forms and Methods of Use Thereof. |
Abstract |
The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof. |
Applicant(s) |
Reata Pharmaceuticals, Inc |
Representative Drug(s) |
D0AX4Q |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0RM4V
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2016033132 |
Title |
Pyridyl Analogs of 1-(2-Cyano-3,12-Dioxooleana-1,9(11)Dien-28-Oyl) Imidazole. |
Abstract |
Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana- 1,9(11 ) -dien-28-oyl) imidazole and pharmaceutical compositions containing the same are provided. The present invention is a tnterpenoid compound of Formula I, or a hydrate, isomer, prodrug or pharmaceutically acceptabl salt thereof: wherein one or more of R, R or R is independently a substituted or unsubstituted aryl group, heteroaryl group, cycloalkyl group or heterocyclyl group, and the remaining R groups are hydrogen. The pyridyl analogs of CDDO-lm 1 have been developed, which are more stable in human plasma and achieve a higher concentration in target tissues such as liver, pancreas, kidney and lungs. |
Applicant(s) |
Trusteses of Dartmouth College |
Representative Drug(s) |
D0KX0J |
Drug Info
|
IC50 = 4.3 nM |
[1] |
Patent ID |
WO2014040073 |
Title |
C13-Hydroxy Derivatives of Oleanolic Acid and Methods of Use Thereof. |
Abstract |
Disclosed herein are novel C13-hydroxy derivatives of oleanolic acid, including those of the formula (I): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided. |
Applicant(s) |
Reata Pharmaceuticals, Inc |
Representative Drug(s) |
D0AJ2T |
Drug Info
|
IC50 = 0.8 nM |
[1] |
Patent ID |
WO2014148455 |
Title |
Terpenoid Derivative. |
Abstract |
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1). |
Applicant(s) |
Daiichi Sankyo Co., Ltd |
Patent ID |
WO2013165140 |
Title |
Benzyl Derivative Compound Containing Activated Vinyl Group Capable of Being Used for Preventing and Treating Neurological Disorders Through Nitric Oxide Generation Inhibition and Nrf2 Activation. |
Abstract |
The present invention relates to: a benzyl derivative containing an activated vinyl group; a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the compound as an ac. |
Applicant(s) |
Korea Institute of Science and Technology |
Representative Drug(s) |
D04ILM |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2012116362 |
Title |
Chalcone Derivatives As Nrf2 Activators. |
Abstract |
Compounds and methods for treating or preventing a disease, disorder or condition associated with an Nrf2-regulated pathway, including those associated with an autoimmune disease, comorbidity associated with diabetes, such as retinopathy and nephropathy, bone marrow transplant for leukemia and related cancers, bone marrow deficiencies, inborn errors of metabolism, and other immune disorders, oxidative stress, respiratory infection, ischemia, neurodegenerative disorders, radiation injury, neutropenia caused by chemotherapy, autoimmunity, and congenital neutropenic disorders, and for restoring a corticosteroid responsiveness, in a subject are provided. |
Applicant(s) |
The Johns Hopkins University |
European Patent Office (EPO) |
Patent ID |
EP2992882 |
Title |
Use of Ergothioneine for Inducing Activity of Nuclear Factor Erythroid 2-Related Factor-2 (Nrf2) In Cell. |
Applicant(s) |
China Medical University |
Representative Drug(s) |
D0N1VC |
Drug Info
|
N.A. |
[1] |
Japan Patent Office (JPO) |
Patent ID |
JP2012082173 |
Title |
Nrf2 Activators Containing 2-Hydroxybenzamide Derivative, Method for Activating Nrf2, and Pharmaceuticals Containing The Compound. |
Applicant(s) |
Keio University |
Representative Drug(s) |
D02YNU |
Drug Info
|
N.A. |
[1] |
Patent ID |
JP2013043851 |
Title |
Anti-Oxidative Stress Enzyme Expression Inducers and Promoters, Nrf2 Activators, and Nrf2 Nuclear Import Promoters. |
Applicant(s) |
Kyorin Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0G4EK |
Drug Info
|
N.A. |
[1] |
China National Intellectual Property Administration (CNIPA) |
Patent ID |
CN105566323 |
Title |
Pyridopyrazine Compounds As Nrf2 Activators and Their Preparation, Pharmaceutical Compositions and Use In The Treatment of Inflammation and Cancer. |
Applicant(s) |
China Pharmaceutical University |
Representative Drug(s) |
D01MZI |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D06LEF
|
Drug Info
|
N.A.
|
[1] |
3
|
D0AZ8T
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
CN105267225 |
Title |
Application of 15,16-Dihydrotanshinone I In Manufacture of Medicament for Protection of Vascular Endothelium. |
Applicant(s) |
China Pharmaceutical University |
Representative Drug(s) |
D0MQ3X |
Drug Info
|
N.A. |
[1] |
Patent ID |
CN104825443 |
Title |
Antioxidant Application of Artemisitene In Composition with Treatment or Health-Care Effect. |
Applicant(s) |
Guangdong Hospital of Traditional Chinese Medicine |
Representative Drug(s) |
D0C1PB |
Drug Info
|
N.A. |
[1] |
Patent ID |
CN104415026 |
Title |
Application of Deuterated Fumaric Acid Derivatives for Treating Multiple Sclerosis. |
Applicant(s) |
Chengdu Sourcebio Limited Liability Company, Peop. Rep. China |
Representative Drug(s) |
D0JH8Z |
Drug Info
|
N.A. |
[1] |
Patent ID |
CN103724198 |
Title |
Derivatives of Dimethyl Fumarate and Application In The Treatment of Multiple Sclerosis. |
Applicant(s) |
Zhenjiang Shengan Pharmaceutical Co., Ltd., Peop. Rep. China |
Representative Drug(s) |
D0JH8Z |
Drug Info
|
N.A. |
[1] |